– USA, CA – Janux Therapeutics today announced the appointment of Vickie Capps and Dr. Sheila Gujrathi, M.D., to its Board as Independent Directors.
Ms. Capps is an experienced senior finance and audit professional with a depth of expertise in strategic business development and corporate governance. Dr. Gujrathi is a seasoned pharmaceutical executive who has successfully founded and built biotech companies and led the advancement and approval of multiple novel biologic and small molecule therapeutics within leading pharmaceutical and biotechnology companies.
“The Board and I are extremely pleased to have Vickie and Sheila joining us as independent directors, and both of their unique skill sets will serve Janux well as we transition to being a clinical-stage company,” said President and CEO, Dr. David Campbell. “Sheila has deep experience and expertise in leading and operating biotech companies and successfully developing innovative drug candidates in immunology and oncology, and Vickie’s distinguished career in finance and management will be critical as Janux accelerates the corporate development of the Company.”
About Vickie Capps
Vickie Capps is a member of the Boards of Directors and the audit committee chair of each of the following public healthcare companies: NuVasive, Inc., Otonomy, Inc., Silverback Therapeutics, Inc. and Amedisys, Inc. Ms. Capps is also a member of the Board of Directors of the San Diego State University Research Foundation and a member of the Senior Advisory Board of Consonance Capital Partners, a healthcare investment firm. She previously served as a member of the Boards of Directors of several other public and private companies, most recently, Synthorx, Inc. and Enclara Pharmacia, Inc. Ms. Capps began her career as an accounting and audit professional at Ernst & Young, followed by chief financial officer roles at several public and private companies. Most recently she was CFO of DJO Global, Inc., a medical device company, from 2002 to 2013.
Ms. Capps is a Certified Public Accountant, and she received her B.S. in business administration and accounting from San Diego State University.
About Dr. Sheila Gujrathi
Dr. Sheila Gujrathi is the co-founder and former CEO of Gossamer Bio, Inc., which is discovering and developing a clinical and research pipeline of novel therapeutics for immunology, inflammation, and oncology. She serves as the Chair of the Board of Directors of Turning Point Therapeutics, Inc. and ADARx Pharmaceuticals, Inc. She previously served on the Board of Directors at Five Prime Therapeutics, Inc. and Ambrx, Inc. Before Gossamer Bio, Dr. Gujrathi served as Chief Medical Officer of Receptos, Inc. At Receptos, she built the development, regulatory, and quality organizations and advanced the pipeline of drug candidates, including Zeposia, which is approved in multiple sclerosis and under Priority Review for ulcerative colitis.
Before Receptos, Dr. Gujrathi was VP, the Global Clinical Development Group in Immunology at Bristol-Myers Squibb, where she led late-stage clinical development and supported numerous global regulatory filings and approvals for Orencia and Nulojix. She was also responsible for the development of other assets in the BMS immunology clinical pipeline and advised the strategies for discovery, early development, and external business development within the immuno-science franchise. Before BMS, Dr. Gujrathi held roles in the immunology, tissue growth, and repair clinical development groups at Genentech, Inc. where she worked on Ocrevus, Rituxan, Xolair, and several other programs across all stages of development and served as the Avastin franchise team leader. Earlier in her career, she was a management consultant in McKinsey & Company’s healthcare practice.
Dr. Gujrathi received both her M.D. in the accelerated Honors Program in Medical Education and her B.S. in biomedical engineering with the highest distinction from Northwestern University. She completed her internal medicine internship and residency at Brigham and Women’s Hospital and Harvard Medical School and additional fellowship training in allergy/immunology at UCSF and Stanford.
About Janux Therapeutics
Janux Therapeutics is developing novel immunotherapies with the company’s proprietary TRACTr technology. Janux’s TRACTr technology employs a modular design to rapidly engineer drug candidates against specific targets and can be applied to immunotherapies that target all three stages of an anti-tumor immune response. Combining Janux’s tumor-specific activation with multi-stage anti-tumor signaling has the potential to significantly improve safety, expand the therapeutic dosing window, and maximize patient responses. The Janux TRACTr development pipeline targets multiple solid tumor indications, including colorectal, gastroesophageal, prostrate, NSCLC, triple-negative breast, and ovarian cancers.
For more information: https://www.januxrx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.